Hutch News

Stories tagged 'merkel cell carcinoma'

Looking back at the future

A roundup of some of our favorite 2016 stories on research at Fred Hutch

Dec. 30, 2016 | By Fred Hutch News Service staff

At Fred Hutch News Service, our writers witness daily the excitement of covering new developments in the science of cancer and the human immune system. As 2016 draws to a close, we asked them to sort through the stories about Fred Hutch research they had written this year, and offer our readers a selection of those they felt were most meaningful and important.

View story >


A new blood test detects recurrence of rare skin cancer

$200 assay can accurately signal return of Merkel cell carcinoma — in some cases catching tumors earlier than expensive imaging

Dec. 12, 2016 | By Rachel Tompa / Fred Hutch News Service

Fred Hutch and UW researchers have developed an inexpensive blood test to catch recurrences of Merkel cell carcinoma -- in some cases the tests finds tumors earlier than traditional imaging.

View story >


'Finally showing hope'

Immunotherapy trial results transforming care for rare skin cancer

April 19, 2016 | By Susan Keown / Fred Hutch News Service

With few remaining options for treating his aggressive Merkel cell carcinoma, Stan Collender joined a clinical trial of the immune-modulating drug pembrolizumab. The trial's results are giving new hope to people with this rare cancer.

View story >


Scratching the surface of a rare skin cancer

Immune-boosting therapy shows promise for advanced Merkel cell carcinoma

Oct. 6, 2015 | By Dr. Rachel Tompa / Fred Hutch News Service

Skin cancer researcher Dr. Paul Nghiem is leading a clinical trial testing the immunotherapy drug pembrolizumab for patients with advanced Merkel cell carcinoma, a rare and aggressive skin cancer. Early results from the trial are showing great promise for these patients.

View story >


After beating rare cancer, 'signing up for Obliteride was a no-brainer'

Keith Winkle will come back to Seattle from Alaska to ride because research saved his life; the Aug. 9-11 bike ride will raise funds to benefit Fred Hutchinson Cancer Research Center

May 24, 2013 | By Justin Matlick

When Keith Winkle was getting radiation treatments at Seattle Cancer Care Alliance, he rode his bike 18 miles from his parents' house to each appointment, then rode all the way back—sometimes with a detour around Lake Washington. It's the kind of commitment to beating cancer—and to cycling—that powers Obliteride, the Aug. 9-11 bike ride to raise funds for Hutchinson Center research. Winkle is training for the event's 100-mile segment.

View story >



GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.